Claudin-18.2
Claudin-18.2 詳細
| 英語名 | Claudin-18 splice variant 2 | 市販薬剤の数 | 1 |
| 治験薬の数 | 85 | ターゲットの別称 | UNQ778/PRO1572，CLDN18，Claudin 18，Surfactant Associated Protein J，Surfactant， Pulmonary Associated Protein J，Surfactant Associated 5，Claudin-18，SFTA5，SFTPJ，Claudin 18.2，CLDN18.2 |
| 研究＆開発段階 | Approved | ||
| 英語名 | Claudin-18 splice variant 2 |
| ターゲットの別称 | UNQ778/PRO1572，CLDN18，Claudin 18，Surfactant Associated Protein J，Surfactant， Pulmonary Associated Protein J，Surfactant Associated 5，Claudin-18，SFTA5，SFTPJ，Claudin 18.2，CLDN18.2 |
| 市販薬剤の数 | 1 |
| 治験薬の数 | 85 |
| 研究＆開発段階 | Approved |
Claudin-18.2 製品リスト
- 属性
Protein (12)Cell (1)Antibody (1)
- 製品ライブラリ
オンライン (14)
- 種
Human / Cynomolgus (6)Human (5)Mouse (3)
- タグ
His Tag & Strep Tag (4)- (7)GFP Tag (1)His Tag & Flag Tag (2)
- マーカー
Unconjugated (8)- (1)GFP Fusion (1)Biotin-labeled (3)PE Labeled (1)
| 製品番号 | 種 | 発現システム | 製品説明 | タンパク質の構造 | 純度 | 特性 |
|---|---|---|---|---|---|---|
 Human | HEK293 | Human Claudin-18.2 Full Length Protein (VLP) |  | |||
 Mouse | InsectCells | Mouse Claudin-18.2 Protein, His,Twin-Strep Tag (Detergent) |  |  | | |
Human / Cynomolgus | InsectCells | Human / Cynomolgus Claudin-18.2 Protein, His,Twin-Strep Tag (Detergent) |  | | ||
HOT CL2-H85D3 | Human / Cynomolgus | InsectCells | Biotinylated Human / Cynomolgus Claudin-18.2 Protein, His,Avitag™&Flag Tag (Detergent) |  | | |
| Human | HEK293 | HEK293/Human Claudin-18.2 Stable Cell Line |  | |||
| Human | E. coli | Human Claudin-18.2 Full Length Protein, Flag,His Tag (Detergent) |  | | ||
| Human | HEK293 | Biotinylated Human Claudin-18.2 Full Length Protein (VLP) | | |||
| Human | HEK293 | Fluorescent Human Claudin-18.2 Full Length Protein (VLP) | | |||
| Mouse | HEK293 | Mouse Claudin-18.2 Full Length Protein (VLP) | | |||
| Mouse | - | Recombinant Monoclonal Anti-Claudin-18.2 Antibody, Mouse (3B10) |
総数量14
- 1
- 2
Claudin-18.2バックグランド
Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.
Claudin-18.2分子の別称
Claudin-18.2,CLDN18,Claudin-18
抗体購入プラットフォーム
| プロジェクト | ステージ | タイプ | 由来 | 疾患領域 | 適応症 |
|---|---|---|---|---|---|
| CLDN18.2 CAR-T - 01 | PhaseI | CAR | Nanobody | Solid Tumor | Advanced refractory gastrointestinal tumors |
| CLDN18.2 VHH - 01 | Lead | Monoclonal | Nanobody | Solid Tumor | Gastric Cancer,Pancreatic cancer |
ライセンシング
| プロジェクト | 薬物タイプ | 治療分野 | 適応症 | ステージ | エリア |
|---|---|---|---|---|---|
| Claudin18.2×CD8+ T bsAb | Bispecific antibody | Oncology/Cancer | Gastric cancer,Pancreatic cancer,Oophoroma | IND | Global |
| CLDN 18.2 CAR-T | Cell therapy | Oncology/Cancer | Gastric Cancer,Pancreatic Cancer | IND | Global |
| Claudin18.2 mAb | Monospecific antibody | Oncology/Cancer | Gastric cancer | Phase I | Global |
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Osemitamab | MSB-018; TST-001 | Phase 3 Clinical | HJB (Hangzhou) Co Ltd, Suzhou Transcenta Therapeutics Co Ltd | Biliary Tract Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| XNW-27011 | XNW-27011 | Phase 3 Clinical | Evopoint Biosciences Co Ltd | Adenocarcinoma; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| IMC-002 (Suzhou Immunofoco) | IMC-002 | Phase 3 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Digestive System Neoplasms; Gastroesophageal Junction Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| Arcotatug tavatecan | IBI-343; IBI343 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Adenocarcinoma; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| LB-4330 | LB-4330; Bis-2 | Phase 3 Clinical | L&L Biopharma Co Ltd | Solid tumours; Uterine Cervical Neoplasms | 詳細 |
| JS-107 | JS-107; JS107 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Adenocarcinoma; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Tecotabart vedotin | TPX-4589; BMS-986476; LM-302 | Phase 3 Clinical | LaNova Medicines Ltd | Adenocarcinoma; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| QLS-31905 | QLS-31905 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Bile Duct Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| SYSA-1801 | SYSA1801; CPO-102; EO-3021; SYSA-1801 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Garetatug Rezetecan | SHR-A-1904; SHR-A1904 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphangioma, Cystic; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| FG-M-108 | FG-M-108; M108; M-108 | Phase 3 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Sonesitatug Vedotin | CMG-901; CMG901; AZD-0901; AZD0901 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| ASKB-589 | ASKB-589 | Phase 3 Clinical | AskGene Pharma Inc, Jiangsu Aosaikang Pharmaceutical Co Ltd | Adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| KD-182 | KD-182 | Phase 2 Clinical | Nanjing Kaidi Medical Technology Co Ltd | Carcinoma, Pancreatic Ductal; Stomach Neoplasms | 詳細 |
| CLDN18.2-TAC T cells Therapy | CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours; Stomach Neoplasms | 詳細 |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| EB-DNK102 | EB-DNK102 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | 詳細 |
| Claudin18.2 targeting CAR-T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Pancreatic Neoplasms | 詳細 | |
| AZD-4360 | AZD4360; AZD-4360 | Phase 2 Clinical | Astrazeneca Ab | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| BDC-4182 | BD-4182; BDC-4182 | Phase 2 Clinical | Bolt Biotherapeutics Inc | Adenocarcinoma; Esophageal Neoplasms; Neoplasms; Stomach Neoplasms | 詳細 |
| LCB-02A | LCB-02A | Phase 2 Clinical | Legochem Biosciences Inc | Hematologic Neoplasms; Solid tumours | 詳細 |
| PM-1032 | PM1032; PM-1032 | Phase 2 Clinical | Shanghai Genechem Co Ltd | Neoplasms; Pancreatic Neoplasms | 詳細 |
| Spevatamig | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| SKB-315 | SKB-315; SKB315; MK1200; MK-1200 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| ATG-022 | ATG-022; ATN-022 | Phase 2 Clinical | Antengene Corporation Co Ltd | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| SOT-102 | SOT-102; SOT102; SO-N102 | Phase 2 Clinical | Sotio Biotech AG | Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| Givastomig | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 | Phase 2 Clinical | I-Mab Biopharma Co Ltd | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Esophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours | 詳細 |
| Recombinant humanized monoclonal antibody MIL93(Mabworks) | MIL-93 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| RC-118 | RC-118; YH005 ADC | Phase 2 Clinical | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 | |
| Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) | AB-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd, Kaixing Life Technology (Shanghai) Co Ltd | Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| KD-496 | KD-496(4th); KD-496 | Phase 1 Clinical | Nanjing Kaidi Medical Technology Co Ltd | Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Claudin18.2 Targeted CAR-T Cells therapy (Frontiergate Biopharm) | Phase 1 Clinical | Frontiergate Biopharm (Hainan) Co Ltd | Pancreatic Neoplasms | 詳細 | |
| Claudin18.2 Targeted Activated Dendritic Cells therapy (Frontiergate Biopharm) | Phase 1 Clinical | Frontiergate Biopharm (Hainan) Co Ltd | Pancreatic Neoplasms | 詳細 | |
| CBG-131 | CBG-131; CBG131 | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| Claudin18.2 CAR-T cell therapy (Ucello Therapeutics) | Phase 1 Clinical | Ucello Therapeutics Co Ltd | Solid tumours | 詳細 | |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms | 詳細 |
| Claudin18.2-targeted CAR-DCs therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Colorectal Neoplasms | 詳細 | |
| Claudin18.2-targeted CAR-T Cells therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Colorectal Neoplasms | 詳細 | |
| CT-225 | XKDCT225; XKDCT-225; CT225 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Solid tumours | 詳細 |
| SIBP-A18 | SIBPA18; SIBP-A18 | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Solid tumours | 詳細 |
| [68Ga]Ga-NODAGA-SNA014 | 68Ga-SNA014; [68Ga]Ga-NODAGA-SNA014; SNA-014 | Phase 1 Clinical | Smartnuclide Biopharma | Adenocarcinoma; Pancreatic Neoplasms | 詳細 |
| HD-004 | HD004; HD-004 | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Solid tumours | 詳細 |
| SPX-102 | SPX-102 | Phase 1 Clinical | Sparx Therapeutics Inc | Neoplasms | 詳細 |
| Cord Blood-Derived CAR-NK Cells therapy (Rongu Biotechnology) | CB CAR-NK182; RG-CLDN18.2 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| LNF-2007 | LNF-2007; LNF2007 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| BL-M05D1 | BL-M05D1; BLM05D1 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Solid tumours; Stomach Neoplasms | 詳細 |
| AHT-102 | AHT102; AHT-102 | Phase 1 Clinical | Guangxi Lugang Biomedical Technology Co Ltd | Solid tumours | 詳細 |
| AZD-6422 | AZD6422; AZD-6422 | Phase 1 Clinical | Astrazeneca Plc | Gastrointestinal Neoplasms | 詳細 |
| GC-506 | GC506; GC-506 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| 68Ga-PMD22(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Gastrointestinal Neoplasms | 詳細 | |
| AK-132 | AK132; AK-132 | Phase 1 Clinical | Neoplasms; Solid tumours | 詳細 | |
| AHT-101 | AHT-101; AHT101 | Phase 1 Clinical | Guangxi Lugang Biomedical Technology Co Ltd | Solid tumours | 詳細 |
| TQB-2103 | TQB2103; TQB-2103 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | 詳細 |
| BIO-008 | BIO-008 | Phase 1 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| BA-1301 | BA-1301; BA1301 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| RB-0011 | RB0011; RB-0011 | Phase 1 Clinical | Ruiyang (Suzhou) Biological Technology Co Ltd | Solid tumours | 詳細 |
| LB-1904 | LB-1904 | Phase 1 Clinical | Stomach Neoplasms | 詳細 | |
| Ori-C-613 | Ori-C-613; OriC-613; Ori-C613 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | 詳細 |
| CT-048 | CT-048; KJ-C1807; KJ-C-1807 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| HEC-016 | HEC-016 | Phase 1 Clinical | People Hospital Of Luohu,Shenzhen | Esophageal Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| PM-3023 | PM-3023 | Phase 1 Clinical | Solid tumours | 詳細 | |
| RD-07 | RD-07 | Phase 1 Clinical | Peking University | Solid tumours | 詳細 |
| IBI-345 | IBI-345 | Phase 1 Clinical | Solid tumours | 詳細 | |
| TORL-2-307-MAB | TORL-2-307-MAB | Phase 1 Clinical | Torl Biotherapeutics LLC | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| TORL-2-307-ADC | TORL-2-307-ADC | Phase 1 Clinical | Torl Biotherapeutics LLC | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| BC-008 | BC-008 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Neoplasms; Solid tumours | 詳細 |
| BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Neoplasms; Solid tumours | 詳細 |
| DR-30303 | DR-30303 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | 詳細 |
| SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Neoplasms; Solid tumours | 詳細 |
| BA-1105 | BA1105; BA-1105 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| CLDN 18.2 CAR-T cell therapy (Shanghai Longyao) | LY-011 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| IBI-389 | IBI-389 | Phase 1 Clinical | Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 | |
| FL-301 | NBL-015; FL-301 | Phase 1 Clinical | Novarock Biotherapeutics Ltd | Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| IBI-360 | IBI-360 | Phase 1 Clinical | Neoplasms; Solid tumours | 詳細 | |
| QL-1779 | QL-1779; QL1779 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| LM-102 | LM-102 | Phase 1 Clinical | LaNova Medicines Ltd | Biliary Tract Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| HBM-1029 | HBM-1029; HBM1029 | Phase 1 Clinical | Harbour Biomed | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| LCAR-C18S CAR-T cell therapy (Legend) | LB-1908; LCAR-C18S; LCAR-C-18-S | Phase 1 Clinical | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 | |
| XKDCT-086 | XKDCT086; XKDCT-086 | Clinical | The Affiliated Hospital Of Qingdao University | Stomach Neoplasms | 詳細 |
| CLDN18.2 UCAR-T cell therapy | CLDN18.2 UCAR-T | Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Stomach Neoplasms | 詳細 |
| 124I-18B10 | 124I-18B10; 124-I-18-B-10 | Clinical | Beijing Cancer Hospital, Transcenta Holding Ltd | Gastrointestinal Neoplasms | 詳細 |
| CTB-001(Nanjing Bioheng) | CTB-001; CTB001 | Clinical | Nanjing Bioheng Biotech Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| 89Zr-NY005 | 89Zr-NY005 | Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Zolbetuximab | GC-182; iMAB-362; IMAB-362 | Approved | Ganymed | Vyloy, VYLOY, 威络益 | Japan | Stomach Neoplasms | Astellas Pharma Inc | 2024-03-26 | Adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphangioma, Cystic; Pain; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
- 詳細
- 製品リスト
- 市販薬剤に関する情報
- 治験薬に関する情報